Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II.

Experimental cell research - 1 Mar 2022

Hong Junjie, Cheng Yu-Shan, Yang Shu, Swaroop Manju, Xu Miao, Beers Jeanette, Zou Jizhong, Huang Wenwei, Marugan Juan J, Cai Xiujun, Zheng Wei

Abstract excerpt

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a rare, lysosomal disorder caused by mutations in a gene encoding iduronate-2-sulfatase (IDS). IDS deficiency results in an accumulation of glycosaminoglycans (GAGs) and secondary accumulations of other lipids in lysosomes. Symptoms of MPS II include a variety of soft and hard tissue problems, developmental delay, and deterioration of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Replacement Therapy
Share to Glycosaminoglycans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iduronate Sulfatase

Share to Lipid Metabolism

Share to Models, Neurological

Share to Mucopolysaccharidosis II

Share to Neural Stem Cells

Share to Tocopherols

Source

Open in PubMed Open full text

Identifiers

PMID: 34990619
DOI: 10.1016/j.yexcr.2021.113007
PMCID: PMC8810712

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II.PMID 34990619Read ↗

Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells.Semantic proximity Read ↗

Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II.Semantic proximity Read ↗

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?Semantic proximity Read ↗

Patient iPSC-derived neural stem cells exhibit phenotypes in concordance with the clinical severity of mucopolysaccharidosis I.Semantic proximity Read ↗

Generation of Mucopolysaccharidosis type II (MPS II) human induced pluripotent stem cell (iPSC) line from a 3-year-old male with pathogenic IDS mutation.Semantic proximity Read ↗

Generation of Mucopolysaccharidosis type II (MPS II) human induced pluripotent stem cell (iPSC) line from a 7-year-old male with pathogenic IDS mutation.Semantic proximity Read ↗

Generation of Mucopolysaccharidosis type II (MPS II) human induced pluripotent stem cell (iPSC) line from a 1-year-old male with pathogenic IDS mutation.Semantic proximity Read ↗

Generation of an induced pluripotent stem cells line, CSSi014-A 9407, carrying the variant c.479C>T in the human iduronate 2-sulfatase (hIDS) gene.Semantic proximity Read ↗

Glial degeneration with oxidative damage drives neuronal demise in MPSII disease.Semantic proximity Read ↗

A novel iPSC model reveals selective vulnerability of neurons in Multiple Sulfatase DeficiencySemantic proximity Read ↗

Generation of human induced pluripotent stem cell (iPSC) line from an unaffected female carrier of Mucopolysaccharidosis type II (MPS II) disorder.Semantic proximity Read ↗

Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanismsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.